Complement Inhibitors Market

Complement Inhibitors Market Overview

The complement inhibitors market is estimated to be worth $6.8 billion in 2022 and is expected to grow at CAGR of over 15% during the forecast period. Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA. In addition, the complement inhibitor drug, EMPAVELITM (pegcetacoplan), which is the first approved complement C3 inhibitor, developed by Apellis Pharmaceuticals, has been approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria; it is believed to bring in new possibilities for the treatment of autoimmune and inflammatory disorders. Discovered in 19th century, complement system is a part of innate immune system and tissue homeostasis, which recognizes, tags and helps to eliminate various disease-causing pathogens. In addition, complement system plays a role in the physiology of a healthy organism (homeostasis) for the removal of apoptotic cells, thereby regulating cell survival. However, inadequate complement activation results in outgrowth of pathogens and suppression of complement regulators, which ultimately becomes a disease cause. As a result, complement-targeted therapeutics have been developed; they inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.

Several drug developers are actively engaged in the development of next generation complement therapeutics with enhanced efficacy. A variety of molecules, such as biologics, gene therapies, oligonucleotides, small interfering RNAs and small molecule-based complement therapeutics are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders. Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future. Moreover, the R&D efforts in this field are also being supported by the National Institutes of Health, which have awarded grants worth USD 837 million for research efforts in this domain over the last few years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of the complement therapeutics is likely to expand. Further, with the encouraging clinical research efforts, broadening of disease focus and efforts to go beyond C5 with innovative approaches that could decrease prices and address safety concerns, the complement therapeutics market is poised to witness steady market growth over the coming years.

Key Companies in Complement Inhibitors Market

Examples of key companies engaged in complement inhibitors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda and UCB. This market report includes an easily searchable excel database of all the companies developing complement inhibitors, worldwide.

Recent Developments in Complement Inhibitors Market:

Several recent developments have taken place in the field of complement inhibitors market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In May 2023, Magenta Therapeutics and Dianthus Therapeutics entered into a merger agreement. The companies will work in collaboration to further advance Dianthus’ range of next generation antibody complement therapeutics. 
• In May 2023, Astellas Pharma signed a definitive agreement to acquire Iveric Bio. Under the terms of the agreement, Iveric’s portfolio of retinal disease drugs will be integrated in Astellas’ portfolio of treatments for eye disorder.

Scope of the Report

The ‘Complement Inhibitors Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration  (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035’ market report features an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the complement inhibitors market. The market research report underlines an in-depth analysis, highlighting the diverse capabilities of players engaged in complement inhibitors market.

Amongst other elements, the market research report includes:

• A detailed review of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), type of drug, biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous), type of therapy (monotherapy and combination therapy) and dosing frequency. In addition, it includes a list of next generation complement therapeutics with special designations. Further, the chapter presents a list of players developing next generation complement therapeutics along with information on their year of establishment, company size and location of headquarters. 
• Detailed profiles of key players engaged in the development of next generation complement therapeutics (shortlisted on the basis of company size). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.
• An in-depth analysis of completed, ongoing and planned clinical studies of various next generation complement therapeutics, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), popular therapeutics area(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
• A detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, which have been published during 2017-2021, based on parameters, such as year of publication, emerging focus areas, top authors, key research journals, popular indication(s) and therapeutic area(s).
• An in-depth analysis of grants awarded to various research institutes for the projects related to next generation complement therapeutics, during period 2017-2021, on the basis of parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section, type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.
• An insightful analysis of the patents filed / granted for next generation complement therapeutics, between 2016- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
• An analysis of the partnerships that have been established in complement inhibitors market since 2014, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, product distribution and commercialization agreement, research and development agreement, and research, development and commercialization agreement and other relevant types of deals.
• A detailed analysis of the various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.
• An analysis of big pharma players engaged in the field of complement inhibitors market, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.

The key objective of complement inhibitors market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for complement inhibitors market during the forecast period. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the forecast period 2022-2035.

Our year wise projections of the current and forecasted opportunity within the complement inhibitors market have further been segmented across [A] Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), [B] Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), [C] Type of Molecule (Biologics and Small Molecules), [D] Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), [E] Type of Therapy (Monotherapy and Combination Therapy), [F] Route of Administration  (Intravenous, Oral and Subcutaneous), [G] Key Geographical Regions (North America, Europe and Asia-Pacific. In order to account for future uncertainties and to add robustness to our model, we have provided three  market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are complement inhibitors?

Answer: Complement inhibitors inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.

Question 2: How big is the complement inhibitors market?

Answer: The complement inhibitors market size is estimated to be worth $6.8 billion in 2022.

Question 3: What is the projected market growth of the complement inhibitors market?

Answer: The complement inhibitors market is expected to grow at compounded annual growth rate (CAGR) of over 15% during the forecast period 2022 - 2035.

Question 4: Who are the leading companies in the complement inhibitors market?

Answer: Examples of key companies engaged in complement inhibitors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda and UCB.

Question 5: How many complement inhibitors are currently being evaluated?

Answer: Currently, over 190 complement inhibitors are being evaluated by companies engaged in the complement inhibitors market.

Question 6: How many players are currently engaged in the complement inhibitors market?

Answer: Presently, more than 45 drug developers are engaged in the complement inhibitors market.

Question 7: Which region is the hub for companies engaged in the complement inhibitors market?

Answer: North America emerged as the hub for companies engaged in the complement inhibitors market, with close to 50% of the players established in the region.